{
    "ticker": "MAIA",
    "name": "Maia Biotechnology, Inc.",
    "description": "Maia Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of cancer. Founded in 2018, Maia is dedicated to addressing the unmet medical needs of cancer patients through innovative approaches and therapies. The company is advancing its lead product candidate, MAIA-101, which is designed to target and destroy cancer cells while sparing healthy cells, thereby minimizing side effects commonly associated with traditional cancer treatments. Maia's research is rooted in a commitment to precision medicine, leveraging cutting-edge technology and scientific expertise to develop targeted therapies that improve patient outcomes. With a robust pipeline and a team of experienced professionals, Maia aims to make significant contributions to the field of oncology and enhance the lives of patients battling cancer. The company is also exploring partnerships and collaborations with other biotech firms and research institutions to accelerate the development of its therapies and expand its reach in the competitive biopharmaceutical landscape.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Chicago, Illinois, USA",
    "founded": "2018",
    "website": "https://www.maiabio.com",
    "ceo": "Michael L. Wiggins",
    "social_media": {
        "twitter": "https://twitter.com/MaiaBiotech",
        "linkedin": "https://www.linkedin.com/company/maia-biotechnology/"
    },
    "investor_relations": "https://www.maiabio.com/investor-relations",
    "key_executives": [
        {
            "name": "Michael L. Wiggins",
            "position": "CEO"
        },
        {
            "name": "Dr. John E. McNulty",
            "position": "Chief Medical Officer"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "MAIA-101"
            ]
        }
    ],
    "seo": {
        "meta_title": "Maia Biotechnology, Inc. | Innovative Cancer Therapies",
        "meta_description": "Learn about Maia Biotechnology, Inc., a clinical-stage biopharmaceutical company dedicated to developing novel cancer therapies. Explore our mission, pipeline, and commitment to patient care.",
        "keywords": [
            "Maia Biotechnology",
            "Cancer Therapy",
            "Biopharmaceuticals",
            "Clinical Trials",
            "MAIA-101"
        ]
    },
    "faq": [
        {
            "question": "What does Maia Biotechnology focus on?",
            "answer": "Maia Biotechnology focuses on developing novel therapeutics for the treatment of cancer."
        },
        {
            "question": "Who is the CEO of Maia Biotechnology?",
            "answer": "Michael L. Wiggins is the CEO of Maia Biotechnology, Inc."
        },
        {
            "question": "Where is Maia Biotechnology headquartered?",
            "answer": "Maia Biotechnology is headquartered in Chicago, Illinois, USA."
        },
        {
            "question": "What is Maia's lead product candidate?",
            "answer": "Maia's lead product candidate is MAIA-101, designed to target cancer cells."
        },
        {
            "question": "When was Maia Biotechnology founded?",
            "answer": "Maia Biotechnology was founded in 2018."
        }
    ],
    "competitors": [
        "NVO",
        "BMY",
        "MRNA",
        "REGN"
    ],
    "related_stocks": [
        "AAPL",
        "GOOGL",
        "AMZN",
        "MSFT"
    ]
}